About Heska (NASDAQ:HSKA)
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products. Its OVP segment includes private label vaccine and pharmaceutical production for cattle but also for other species, including equine, porcine, avian, feline and canine. All OVP products are sold by third parties under third-party labels. It focuses on supporting veterinarians in canine and feline healthcare space. It offers a line of veterinary blood testing and other instruments. It manufactures biological and pharmaceutical products for other animal health companies.
Industry, Sector and Symbol
Trailing P/E Ratio59.6645775921954
Forward P/E Ratio40.11
Sales & Book Value
Annual Sales$129.34 million
Price / Sales4.42
Cash Flow$2.83 per share
Price / Cash27.60
Book Value$13.87 per share
Price / Book5.64
Net Income$9.95 million
Return on Equity16.23%
Return on Assets11.93%
Heska (NASDAQ:HSKA) Frequently Asked Questions
What is Heska's stock symbol?
Heska trades on the NASDAQ under the ticker symbol "HSKA."
How were Heska's earnings last quarter?
Heska Corp (NASDAQ:HSKA) posted its earnings results on Wednesday, February, 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.07. The medical research company earned $36.04 million during the quarter, compared to analysts' expectations of $40.56 million. Heska had a return on equity of 16.23% and a net margin of 7.53%. The firm's quarterly revenue was down 8.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.46 earnings per share. View Heska's Earnings History.
When will Heska make its next earnings announcement?
Where is Heska's stock going? Where will Heska's stock price be in 2018?
6 equities research analysts have issued 1 year price targets for Heska's shares. Their predictions range from $77.00 to $129.50. On average, they anticipate Heska's share price to reach $103.10 in the next year. View Analyst Ratings for Heska.
What are Wall Street analysts saying about Heska stock?
Here are some recent quotes from research analysts about Heska stock:
- 1. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (1/3/2018)
- 2. B. Riley analysts commented, "We expect Q3 results to be generally in line. We forecast revenue of $35.8 million and EPS of $0.40 versus consensus of $36.0 million and EPS of $0.41. We model revenue growth at 7.1%, reflecting ongoing momentum in core blood diagnostics within its Core Companion Animal Health offset by Other Vaccines, Pharmaceuticals and Products segment which pulled forward revenue last quarter (but expecting to finish off Q4 strong)." (10/27/2017)
Who are some of Heska's key competitors?
Some companies that are related to Heska include G1 Therapeutics (GTHX), Myovant Sciences (MYOV), Revance Therapeutics (RVNC), TherapeuticsMD (TXMD), Bavarian Nordic (BVNRY), DBV Technologies (DBVT), Audentes Therapeutics (BOLD), Athenex (ATNX), Intellia Therapeutics (NTLA), Zai Lab (ZLAB), Adaptimmune Therapeutics (ADAP), Dynavax Technologies (DVAX), Retrophin (RTRX), Amarin (AMRN), Biohaven Pharmaceutical (BHVN), Alder Biopharmaceuticals (ALDR), Regenxbio (RGNX) and Mirati Therapeutics (MRTX).
Who are Heska's key executives?
Heska's management team includes the folowing people:
- Sharon J. Larson, Independent Chairman of the Board (Age 55)
- Kevin S. Wilson, President, Chief Executive Officer, Director (Age 44)
- Catherine Grassman, Principal Financial Officer, Principal Accounting Officer, Vice President, Controller (Age 41)
- Michael J. McGinley Ph.D., President - Biologicals & Pharmaceuticals (Age 56)
- Jason A. Napolitano, Chief Operating Officer, Chief Strategist and Secretary (Age 48)
- Steven M. Eyl, Executive Vice President - Global Sales and Marketing (Age 51)
- Steven M. Asakowicz, Executive Vice President - Companion Animal Health Sales (Age 51)
- Rodney A. Lippincott, Executive Vice President - Companion Animal Health Sales (Age 43)
- Nancy Wisnewski Ph.D., Executive Vice President - Diagnostic Operations and Product Development (Age 54)
- Scott Humphrey, Director
Has Heska been receiving favorable news coverage?
News stories about HSKA stock have trended positive this week, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Heska earned a media sentiment score of 0.26 on Accern's scale. They also gave headlines about the medical research company an impact score of 43.76 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Heska's major shareholders?
Heska's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.16%), Park West Asset Management LLC (4.80%), TimesSquare Capital Management LLC (4.10%), Bank of New York Mellon Corp (2.91%), Riverbridge Partners LLC (2.75%) and Redmile Group LLC (2.71%). Company insiders that own Heska stock include Carol Wrenn, G Irwin Gordon, Jason A Napolitano, John Mcmahon, Kevin S Wilson, Michael J Mcginley, Nancy Wisnewski, Rod Lippincott, Sharon J Larson, Sharon L Riley and Steve Asakowicz. View Institutional Ownership Trends for Heska.
Which institutional investors are selling Heska stock?
HSKA stock was sold by a variety of institutional investors in the last quarter, including Cornerstone Capital Management Holdings LLC., Goldman Sachs Group Inc., Globeflex Capital L P, Raymond James & Associates, Martingale Asset Management L P, Alliancebernstein L.P., Allianz Asset Management GmbH and Guggenheim Capital LLC. Company insiders that have sold Heska company stock in the last year include Carol Wrenn, Jason A Napolitano, John Mcmahon, Michael J Mcginley, Nancy Wisnewski, Rod Lippincott and Steve Asakowicz. View Insider Buying and Selling for Heska.
Which institutional investors are buying Heska stock?
HSKA stock was bought by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Park West Asset Management LLC, Redmile Group LLC, Ranger Investment Management L.P., Bank of New York Mellon Corp, Tygh Capital Management Inc., Fred Alger Management Inc. and Royce & Associates LP. View Insider Buying and Selling for Heska.
How do I buy shares of Heska?
Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heska's stock price today?
One share of HSKA stock can currently be purchased for approximately $78.22.
How big of a company is Heska?
Heska has a market capitalization of $573.49 million and generates $129.34 million in revenue each year. The medical research company earns $9.95 million in net income (profit) each year or $1.31 on an earnings per share basis. Heska employs 345 workers across the globe.
How can I contact Heska?
Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]
MarketBeat Community Rating for Heska (HSKA)MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Heska (NASDAQ:HSKA) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Hold|
|Consensus Rating Score: ||2.83||2.83||2.67||2.40|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$103.10||$110.30||$114.38||$104.25|
|Price Target Upside: ||31.81% upside||53.69% upside||39.96% upside||2.55% upside|
Heska (NASDAQ:HSKA) Consensus Price Target History
Heska (NASDAQ:HSKA) Analyst Ratings History
(Data available from 3/20/2016 forward)
Heska (NASDAQ:HSKA) Earnings History and Estimates Chart
Heska (NASDAQ HSKA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2018|| || || || || || || || |
|2/28/2018||Q4 2017||$0.56||$0.63||$40.56 million||$36.04 million||View||N/A|
|11/2/2017||Q3 2017||$0.37||$0.40||$36.10 million||$31.40 million||View||N/A|
|8/3/2017||Q2 2017||$0.37||$0.44||$33.35 million||$34.30 million||View||N/A|
|5/2/2017||Q1 2017||$0.24||$0.61||$33.31 million||$30.38 million||View||Listen|
|2/28/2017||Q416||$0.37||$0.46||$34.56 million||$39.50 million||View||Listen|
|11/1/2016||Q316||$0.26||$0.45||$31.36 million||$33.40 million||View||N/A|
|8/3/2016||Q216||$0.18||$0.35||$28.47 million||$30.00 million||View||N/A|
|5/3/2016||Q116||($0.02)||$0.17||$23.32 million||$27.10 million||View||N/A|
|3/3/2016||Q415||$0.17||$0.28||$28.31 million||$29.80 million||View||N/A|
|11/11/2015||Q315||$0.08||$0.20||$24.31 million||$28.00 million||View||Listen|
|7/29/2015||Q215||$0.10||$0.17||$24.11 million||$23.90 million||View||Listen|
|5/7/2015||Q115||$0.09||$0.09||$23.97 million||$22.90 million||View||N/A|
|3/5/2015||Q414||$0.15||$0.12||$24.20 million||$24.30 million||View||N/A|
|10/29/2014||Q3 2014||($0.01)||$0.08||$19.39 million||$21.81 million||View||N/A|
|7/30/2014||Q2||($0.03)||$0.17||$19.78 million||$22.92 million||View||N/A|
|5/8/2014||Q1 2014||($0.01)||$0.03||$20.31 million||$20.79 million||View||N/A|
|3/27/2014||$0.04||$0.20||$18.84 million||$23.50 million||View||N/A|
|11/6/2013||Q3 2013||($0.11)||$0.04||$18.26 million||$17.60 million||View||N/A|
|8/7/2013||Q2 2013||($0.01)||($0.38)||$19.85 million||$18.30 million||View||N/A|
|5/14/2013||Q1 2013||$0.12||($0.07)||$20.94 million||$18.98 million||View||N/A|
|11/13/2012||Q312||$0.08||($0.01)||$19.70 million||$16.90 million||View||N/A|
Heska (NASDAQ:HSKA) Earnings Estimates
2018 EPS Consensus Estimate: $1.99
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Heska (NASDAQ:HSKA)
No dividend announcements for this company have been tracked by MarketBeat.com
Heska (NASDAQ HSKA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.70%
Institutional Ownership Percentage: 85.21%
Heska (NASDAQ HSKA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/29/2017||Michael J Mcginley||Insider||Sell||7,826||$87.14||$681,957.64||106,771|| |
|11/27/2017||Michael J Mcginley||Insider||Sell||1||$88.54||$88.54||106,771|| |
|8/31/2017||Nancy Wisnewski||EVP||Sell||825||$102.21||$84,323.25||38,114|| |
|8/30/2017||John Mcmahon||CFO||Sell||2,608||$101.17||$263,851.36||193|| |
|6/1/2017||Steve Asakowicz||EVP||Sell||382||$100.08||$38,230.56||10,382|| |
|5/31/2017||Michael J Mcginley||Insider||Sell||11,189||$98.53||$1,102,452.17||111,877|| |
|5/31/2017||Rod Lippincott||EVP||Sell||11,227||$98.00||$1,100,246.00||11,292|| |
|5/24/2017||Jason A. Napolitano||COO||Sell||5,000||$100.50||$502,500.00|| |
|5/24/2017||Nancy Wisnewski||EVP||Sell||250||$100.17||$25,042.50||38,901|| |
|5/23/2017||Carol Wrenn||Director||Sell||1,630||$96.95||$158,028.50||6,174|| |
|5/23/2017||John Mcmahon||CFO||Sell||587||$97.00||$56,939.00||295|| |
|5/4/2017||Sharon J Larson||Director||Buy||1,000||$90.00||$90,000.00||3,294|| |
|4/11/2017||Jason A. Napolitano||COO||Sell||1,100||$102.98||$113,278.00|| |
|4/10/2017||Jason A. Napolitano||COO||Sell||3,900||$102.94||$401,466.00|| |
|3/9/2017||John Mcmahon||CFO||Sell||708||$97.42||$68,973.36||200|| |
|3/9/2017||Rod Lippincott||EVP||Sell||5,157||$97.87||$504,715.59||10,513|| |
|3/6/2017||Kevin S Wilson||CEO||Sell||8,000||$90.00||$720,000.00||110,000|| |
|1/10/2017||Jason A. Napolitano||COO||Sell||5,000||$74.73||$373,650.00|| |
|11/29/2016||G Irwin Gordon||Director||Sell||3,000||$66.11||$198,330.00||17,596|| |
|11/28/2016||John Mcmahon||CFO||Sell||1,999||$65.64||$131,214.36||584|| |
|11/22/2016||Rod Lippincott||EVP||Sell||5,000||$64.85||$324,250.00||10,192|| |
|9/1/2016||Jason A. Napolitano||CFO||Sell||5,000||$52.53||$262,650.00|| |
|8/29/2016||Kevin S Wilson||CEO||Sell||20,000||$51.80||$1,036,000.00||110,000|| |
|8/24/2016||John Mcmahon||VP||Sell||137||$51.30||$7,028.10|| |
|8/9/2016||Steve Asakowicz||EVP||Sell||4,698||$52.55||$246,879.90||12,858|| |
|8/3/2016||Kevin S Wilson||CEO||Sell||30,736||$47.34||$1,455,042.24||140,720|| |
|7/29/2016||Kevin S Wilson||CEO||Sell||20||$43.95||$879.00||140,736|| |
|7/20/2016||Kevin S Wilson||CEO||Sell||3,779||$44.02||$166,351.58||140,756|| |
|7/18/2016||Kevin S Wilson||CEO||Sell||5,465||$44.31||$242,154.15||144,535|| |
|7/8/2016||Kevin S Wilson||CEO||Sell||10,000||$42.37||$423,700.00||150,000|| |
|7/7/2016||Jason A. Napolitano||CFO||Sell||20,000||$41.00||$820,000.00|| |
|7/6/2016||Kevin S Wilson||CEO||Sell||5,960||$40.27||$240,009.20||160,000|| |
|7/1/2016||Kevin S Wilson||CEO||Sell||14,040||$38.94||$546,717.60||165,960|| |
|6/2/2016||Kevin S Wilson||CEO||Sell||20,000||$36.74||$734,800.00||190,000|| |
|5/12/2016||Kevin S Wilson||CEO||Sell||5,000||$38.50||$192,500.00||200,000|| |
|5/10/2016||Kevin S Wilson||CEO||Sell||15,000||$36.75||$551,250.00||210,000|| |
|5/10/2016||Michael J Mcginley||Insider||Sell||5,998||$36.50||$218,927.00||30,801|| |
|5/10/2016||Sharon L Riley||Director||Sell||5,000||$36.87||$184,350.00||9,500|| |
|5/9/2016||Kevin S Wilson||CEO||Sell||11,000||$35.61||$391,710.00||228,718|| |
|5/5/2016||Sharon L Riley||Director||Sell||15,000||$35.66||$534,900.00||9,500|| |
|5/3/2016||Jason A Napolitano||CFO||Sell||5,000||$35.75||$178,750.00||63,544|| |
|3/8/2016||Sharon L Riley||Director||Buy||1,000||$32.49||$32,490.00||5,500|| |
|1/27/2016||Jason A Napolitano||CFO||Sell||15,000||$37.00||$555,000.00||51,900|| |
|12/29/2015||Jason A. Napolitano||CFO||Sell||3,700||$40.03||$148,111.00||66,900|| |
|12/3/2015||Kevin S Wilson||CEO||Sell||6,000||$35.50||$213,000.00||230,000|| |
|11/25/2015||Michael J. Mcginley||insider||Sell||958||$33.62||$32,207.96||15,928|| |
|11/24/2015||Michael J. Mcginley||insider||Sell||1,427||$33.33||$47,561.91||15,928|| |
|9/11/2015||Jason A Napolitano||CFO||Sell||1,699||$33.51||$56,933.49||58,100|| |
|8/31/2015||Jason A. Napolitano||CFO||Sell||4,998||$33.59||$167,882.82||59,799|| |
|8/31/2015||Robert B. Grieve||insider||Sell||11,098||$33.77||$374,779.46||101,690|| |
|8/27/2015||Robert B. Grieve||insider||Sell||3,604||$33.79||$121,779.16||101,690|| |
|8/17/2015||Kevin S Wilson||CEO||Sell||2,498||$34.90||$87,180.20|| |
|8/17/2015||Robert B Grieve||Insider||Sell||8,033||$34.91||$280,432.03|| |
|8/14/2015||Kevin S Wilson||CEO||Sell||2,101||$34.90||$73,324.90|| |
|8/14/2015||Rod Lippincott||EVP||Sell||3,898||$34.19||$133,272.62|| |
|7/13/2015||Robert B Grieve||Insider||Sell||1,000||$29.99||$29,990.00|| |
|6/8/2015||Kevin S Wilson||CEO||Sell||11,810||$30.08||$355,244.80|| |
|6/3/2015||Robert B Grieve||Insider||Sell||17,000||$31.36||$533,120.00|| |
|6/1/2015||Jason A Napolitano||CFO||Sell||7,536||$32.26||$243,111.36|| |
|5/22/2015||Steven M Eyl||EVP||Sell||5,981||$30.19||$180,566.39|| |
|4/24/2015||Robert B Grieve||Insider||Sell||6,000||$29.67||$178,020.00|| |
|4/13/2015||Robert B Grieve||Insider||Sell||4,000||$26.54||$106,160.00|| |
|3/9/2015||Jason A Napolitano||CFO||Sell||5,765||$26.02||$150,005.30|| |
|3/9/2015||Kevin S Wilson||CEO||Sell||10,000||$25.38||$253,800.00|| |
|3/9/2015||Robert B Grieve||Insider||Sell||2,000||$25.26||$50,520.00|| |
|11/30/2014||David E Sveen||Director||Buy||21,428||$14.00||$299,992.00|| |
|11/30/2014||Kevin S Wilson||CEO||Sell||28,928||$14.00||$404,992.00|| |
|11/21/2014||Robert B Grieve||Insider||Sell||6,500||$15.25||$99,125.00|| |
|11/3/2014||William A Aylesworth||Director||Sell||5,000||$13.67||$68,350.00|| |
|8/4/2014||Robert B Grieve||Director||Sell||12,000||$13.57||$162,840.00|| |
|5/14/2014||William Aylesworth||Director||Sell||4,200||$10.89||$45,738.00||29,797|| |
|3/31/2014||Carol Wrenn||Director||Buy||1,000||$10.50||$10,500.00||4,000|| |
|3/31/2014||Robert Grieve||CEO||Sell||7,000||$10.50||$73,500.00||143|| |
|3/1/2013||William A Aylesworth||Director||Buy||2,000||$8.34||$16,680.00|| |
|10/3/2012||Master Fund L.P. Cmc||Major Shareholder||Sell||11,002||$9.54||$104,959.08|| |
|8/28/2012||William A Aylesworth||Director||Buy||2,000||$7.95||$15,900.00|| |
Heska (NASDAQ HSKA) News Headlines
Heska (NASDAQ:HSKA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Heska (NASDAQ:HSKA) Income Statement, Balance Sheet and Cash Flow Statement
Heska (NASDAQ HSKA) Stock Chart for Tuesday, March, 20, 2018